+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis



Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis



Hepatology 38(4 Suppl 1): 296A



Studies dealing with the prevention of rebleeding have shown that hemodynamic response to pharmacological treatment of portal hypertension is adequate when the hepatic venous pressure gradient (HVPG) decreases to ?12mmHg or by ?20% from baseline. With beta-blockers these targets are achieved in only around 30% of cases. However, even with such a high rate of poor hemodynamic response, variceal bleeding occurs in few patients when beta-blockers are used for primary prophylaxis (around 15%). The aim of this study was to assess whether the cut-off value to define response in primary prophylaxis may be defined more accurately and to investigate whether the acute response to beta-blockers may predict evolution (avoiding a second study). METHODS: A total of 101 cirrhotic patients with large varices and without previous bleeding were investigated. A baseline hemodynamic study was performed in all patients. After, initial measurements, propranolol was administered in 55 patients (0.15mg/kg i.v.) and measurements were repeated 20 minutes later. Subsequently, nadolol was chronically administered to prevent variceal bleeding. A second hemodynamic study was performed 1 to 3 months later in 72 patients. RESULTS: During a mean follow-up of 37 months, 17% of patients had a bleeding episode and 19% died. There was a significant correlation between acute and chronic hemodynamic response to beta-blockers (r=0.6, P=0.001). Using ROC curve a decrease of HVPG ?10% from baseline was the better cut-off point to predict bleeding, both for acute and chronic studies. Hemodynamic responders (defining response as a decrease of HVPG to ?12mmHg or ?10%), had a significantly lower probability of bleeding (P?0.01) and of requiring hospital admission because decompensations of cirrhosis, while survival probability was higher, both after acute and chronic beta-blocker administration. The HVPG decreased ?20% in 38% of cases and decreased ?10% in 74% (P?0.001) after acute beta-blocker. These figures were 31% vs 68% (P?0.001) after a chronic administration. CONCLUSIONS: Our results suggest that: 1) A decrease of HVPG ?10% from baseline may be the target to identify hemodynamic responders in primary prophylaxis of variceal bleeding; 2) Acute hemodynamic response to beta-blockers may provide an accurate prognostic information on long-term risk of variceal bleeding.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035023989

Download citation: RISBibTeXText

DOI: 10.1016/s0270-9139(03)80334-8


Related references

Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 137(1): 119-128, 2009

A multicenter controlled study comparing beta-blockers and beta-blockers plus nitroderivatives in the primary prophylaxis of first variceal bleeding in cirrhosis Interim analysis. Hepatology 18(4 Part 2): 283A, 1993

The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 32(5): 930-934, 2000

Hemodynamic response to primary prophylactic therapy with nonselective -blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis. European Journal of Gastroenterology & Hepatology 29(4): 380-387, 2017

Acute and chronic hemodynamic changes after propranolol in patients with cirrhosis under primary and secondary prophylaxis of variceal bleeding: a pilot study. European Journal of Gastroenterology and Hepatology 22(5): 507-512, 2010

Acute variceal bleeding in patients on primary prophylaxis with nonselective beta-blockers: A poor prognosis factor?. Hepatology 65(5): 1774, 2017

Use of beta-blockers for primary prophylaxis of variceal bleeding. Journal of Pediatric Gastroenterology and Nutrition 31(1): 93-94, 2000

Hemodynamic response to medical treatment as a predictive factor of efficacy of prophylaxis of the first variceal bleeding in cirrhotic patients. Hepatology 32(4 Pt 2): 517A, 2000

Efficacy of beta-blockers as secondary prophylaxis in variceal bleeding after TIPS therapy. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A148, 2000

Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both?. American Journal of Gastroenterology 100(4): 805-807, 2005

Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: A decision analytic model. American Journal of Gastroenterology 98(4): 763-770, 2003

Effectiveness of beta blockers in primary prophylaxis of variceal bleeding in children with portal hypertension. Tropical Gastroenterology 32(4): 299-303, 2012

Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Alimentary Pharmacology & Therapeutics 21(12): 1435-1443, 2005

Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Annals of Hepatology 11(3): 369-383, 2012

Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. Journal of Hepatology 54(6): 1161-1167, 2011